A statement released earlier today by Liberum Capital about Shire PLC (LON:SHP) maintains the target price at 5,500.00GBX
- Updated: September 18, 2016
Showing a price of 5,104.50GBX, Shire PLC (LON:SHP) traded 3.22% higher on the day. With the last stock close up 15.37% relative to the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. SHP has been tracking to a 50-day average of 4,943.59GBX and two hundred day moving average of 4,416.34GBX. 4,917,584 shares of Shire PLC were exchanged, up from ann average trading volume of 2,157,220
Liberum Capital held the price target of Shire PLC (LON:SHP) at 5,500GBX, stating a possible upside of 0.08%,
On 9/14/2016, Exane BNP Paribas reported on Shire PLC(LON:SHP) maintained the target price at 5,900.00GBX. At the time, this suggested an upside of 0.22%.
See Chart Below:
A total of 18 brokers have reported on the stock. Six firms rate the stock a strong buy, 16 firms rate the company a buy, 0 firms rate the stock a hold, 0 rate the company to underperform, and lastly 0 brokeragesrate the company as sell with a 12-month target of 73.73GBX
Shire PLC has a P/E of 32 with a one-year low of 2,707.19GBX and a one-year high of 5,562.83GBX and has a market capitalization of 0.0 GBX.
About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), and GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.